44 related articles for article (PubMed ID: 18774636)
1. Isolation and characterization of human anti-VEGF165 monoclonal antibody with anti-tumor efficacy from transgenic mice expressing human immunoglobulin loci.
Liu Y; Yun DJ; Chen JQ; Zhao JY; Liu SG; Cheng GX
Cancer Lett; 2009 Jan; 273(1):28-34. PubMed ID: 18774636
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of human anti-acetylcholine receptor monoclonal antibodies from transgenic mice expressing human immunoglobulin loci.
Protopapadakis E; Kokla A; Tzartos SJ; Mamalaki A
Eur J Immunol; 2005 Jun; 35(6):1960-8. PubMed ID: 15915538
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
4. Human monoclonal antibodies produced in transgenic BABkappa,lambda mice recognising idiotypic immunoglobulins of human lymphoma cells.
Suárez E; Yáñez R; Barrios Y; Díaz-Espada F
Mol Immunol; 2004 Jul; 41(5):519-26. PubMed ID: 15183930
[TBL] [Abstract][Full Text] [Related]
5. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
6. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies.
Gerber HP; Wu X; Yu L; Wiesmann C; Liang XH; Lee CV; Fuh G; Olsson C; Damico L; Xie D; Meng YG; Gutierrez J; Corpuz R; Li B; Hall L; Rangell L; Ferrando R; Lowman H; Peale F; Ferrara N
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3478-83. PubMed ID: 17360669
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
[TBL] [Abstract][Full Text] [Related]
8. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
9. The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells.
Ge YL; Zhang X; Zhang JY; Hou L; Tian RH
Int Immunopharmacol; 2009 Apr; 9(4):389-95. PubMed ID: 19162240
[TBL] [Abstract][Full Text] [Related]
10. [Nanogold inhibits angiogenesis and growth of liver cancer: experiment with mice].
Pan YL; Qiu SY; Qin L; Cai JY; Sun JS
Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):800-4. PubMed ID: 19595116
[TBL] [Abstract][Full Text] [Related]
11. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics.
Liu XY; Pop LM; Roopenian DC; Ghetie V; Vitetta ES; Smallshaw JE
Int Immunopharmacol; 2006 May; 6(5):791-9. PubMed ID: 16546710
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of monoclonal anti-epidermal growth factor receptor antibody (IOR EGF/r3)-induced apoptosis in human carcinoma bearing nude mice.
Ducongé J; Merino N; Alvarez D; Beausoleil I; Fernández-Sánchez E; Rodríguez L; Burt AD
P R Health Sci J; 2008 Mar; 27(1):35-41. PubMed ID: 18450231
[TBL] [Abstract][Full Text] [Related]
14. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference.
Wang J; Shi YQ; Yi J; Ye S; Wang LM; Xu YP; He M; Kong XM
J Dig Dis; 2008 Nov; 9(4):228-37. PubMed ID: 18959596
[TBL] [Abstract][Full Text] [Related]
15. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor.
Imai N; Miwa H; Shikami M; Suganuma K; Gotoh M; Hiramatsu A; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Shitara K; Shibuya M; Nitta M
Leuk Res; 2009 Dec; 33(12):1650-7. PubMed ID: 19342098
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity.
Hanaoka H; Katagiri T; Fukukawa C; Yoshioka H; Yamamoto S; Iida Y; Higuchi T; Oriuchi N; Paudyal B; Paudyal P; Nakamura Y; Endo K
Ann Nucl Med; 2009 Jul; 23(5):479-85. PubMed ID: 19412654
[TBL] [Abstract][Full Text] [Related]
18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.
Shin JY; Yoon IH; Kim JS; Kim B; Park CG
Cell Immunol; 2009; 256(1-2):72-8. PubMed ID: 19249018
[TBL] [Abstract][Full Text] [Related]
20. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
